Alphamab Oncology raises more than $100M series A

Immuno-oncology company Alphamab Oncology (Cayman) raised over $100 million in a series A round to accelerate development of its biologics including lead product KN035. Advantech Capital, PAG, China Venture Capital Fund, OrbiMed Advisors, Heritage Provider Network and Janchor Partners participated in the round.

SVP of Corporate Development Mike Liu told BioCentury the funding would be used for additional clinical testing, expanding the company’s clinical development and precommercial teams and completing development of its cGMP biologics production facility...